1Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther, 1985, 234:1 - 12
2Jaffe JH. Tobacco smoking and nicotine dependence. In:Wonnacott S, Russell MAH, Stderman IP, eds. Nicotine psychopharmacology: molecular, cellular and behavioral aspects. New York: Oxford Press, 1990. 1--37
3Stolerman I, Jarvis M. The scientific case that nicotine is addictive. Psyhopharmacology, 1995, 117: 2- 10
4Rennard SI, Daughton DM. Cigarette smoking and disease. In: Elias JA, Fishman JZ, Grippi MA, eds. Pulmonary diseases and disorders. New York; McGraw Hill, 1997. 697-708
5Shadel WG, Shiffman S, Niaura R, et al. Current models of nicotine dependence: what is known and what is needed to advance understanding of tobacco etiology among youth. Drug Alcohol Depend, 2000, 59 [Suppl 1]: S9-S21
6Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the comorbidity survey. Exp Clin Psychopharmacol, 1994, 2: 244- 268
7Fiscella K, Franks P. Cost- effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA, 1996, 275: 1247-1251
8Wise RA. Drug- activation of brain reward pathways. Drug Alcohol Depend, 1998, 51: 13 - 22
9Dale LC, Ebbert JO, Hays JT, et al. Treatment of nicotine dependence, Mayo Clin Proc, 2000, 75:1311 - 1316
10Shiffman S, Pinney JM, Gitchell J, et al. Public health benefit of over - the - counter nicotine medications. Tob Control, 1997, 6:306-310
